OPEN-LABEL, PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AZD5492 FOLLLOWING SINGLE-ASCENDING DOSE AND STEP-UP DOSE ADMINISTRATION TO ADULT PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATUS OR IDIOPATIC INFLAMMATORY MYOPATIES
- Registry ID
- D9961C00001
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA AB
- Last update
- 2025-04-03
Conditions
- IDIOPATHIC INFLAMMATORY MYOPATHY
- LUPUS ERYTHEMATOSUS
Related clinical trials
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS
- A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS
ERYTHEMATOSUS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF ANIFROLUMAB IN ADULTS WITH CHRONIC AND/OR SUBACUTE
CUTANEOUS LUPUS ERYTHEMATOSUS WHO ARE REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL
THERAPY
- A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE 3, LONG-TERM EXTENSION STUDY TO EVALUATE CONTINUOUS SAFETY AND EFFICACY OF BIIB059 (LITIFILIMAB) IN ADULT PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYT
- A PHASE 3 PROGRAM TO EVALUATE THE SAFETY AND EFFICACY OF UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SLE
- A PHASE 3, SINGLE-ARM, MULTICENTER, OPEN-LABEL EXTENSION OF STUDY ARGX-113-2007 TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY
View on source registry